Namely, comparing the known KRAS mutations to the different mutation signatures present in each tumor revealed that while most oncogenic KRAS mutations tracked to the dominant mutation signature of each tumor, nearly a quarter of the KRASG12/13C mutations tracked with a minor mutation signature (Fig 5B). This evidence concerns the gene KRAS and neoplasm.